Top Page
BeiGene Ltd
(6160)
BeiGene Ltd (6160) vs. iShares MSCI Hong Kong ETF (EWH)
BeiGene Ltd Business Overview & Revenue Model
BeiGene Ltd Earnings Call Summary
BeiGene Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.97B | 3.81B | 2.46B | 1.42B | 1.18B | 308.87M |
| Gross Profit | 4.29B | 3.22B | 2.08B | -511.06M | -447.86M | -1.06B |
| EBITDA | 338.62M | -396.44M | -1.12B | -1.72B | -1.39B | -1.63B |
| Net Income | 68.55M | -644.79M | -881.71M | -2.00B | -1.46B | -1.62B |
Balance Sheet | ||||||
| Total Assets | 7.63B | 5.92B | 5.81B | 6.38B | 8.65B | 5.60B |
| Cash, Cash Equivalents and Short-Term Investments | 4.04B | 2.63B | 3.17B | 4.53B | 6.62B | 4.65B |
| Total Debt | 1.02B | 1.08B | 930.18M | 596.67M | 694.64M | 561.96M |
| Total Liabilities | 3.50B | 2.59B | 2.27B | 2.00B | 2.40B | 1.73B |
| Stockholders Equity | 4.13B | 3.33B | 3.54B | 4.38B | 6.24B | 3.87B |
Cash Flow | ||||||
| Free Cash Flow | 463.90M | -669.77M | -1.75B | -1.97B | -1.61B | -1.51B |
| Operating Cash Flow | 785.39M | -140.63M | -1.16B | -1.50B | -1.30B | -1.28B |
| Investing Cash Flow | -331.43M | -548.35M | 60.00M | 1.08B | 640.66M | -3.17B |
| Financing Cash Flow | 958.00M | 193.45M | 416.48M | -18.97M | 3.64B | 5.20B |
BeiGene Ltd Technical Analysis
BeiGene Ltd Risk Analysis
BeiGene Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$233.12B | 44.35 | 16.09% | 0.95% | 8.68% | 0.82% | |
69 Neutral | HK$299.18B | 18.57 | 25.65% | 1.75% | 11.55% | 64.46% | |
63 Neutral | HK$141.02B | 30.65 | 9.79% | ― | 16.90% | 63.11% | |
61 Neutral | HK$143.26B | 112.08 | 8.41% | ― | 52.78% | ― | |
54 Neutral | HK$277.85B | 595.18 | -4.94% | ― | 49.63% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
BeiGene Ltd Corporate Events
BeOne Medicines Ltd., a Swiss corporation listed on the Hong Kong Stock Exchange, announced the grant of 21,274 Restricted Share Units (RSUs) to 147 employees under its 2016 Share Option and Incentive Plan. This grant represents approximately 0.02% of the company’s total issued shares. The RSUs will vest over four years, subject to continued employment, with specific conditions for accelerated vesting in certain cases. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.
BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland, announced the grant of Restricted Share Units (RSUs) under its 2016 Share Option and Incentive Plan. On November 10, 2025, the company’s compensation committee granted a total of 16,463 RSUs, equivalent to 214,019 underlying shares, to 143 employees, representing approximately 0.01% of the total issued shares. The RSUs will vest over four years, with specific conditions for accelerated vesting. This move is part of BeOne’s strategy to incentivize its workforce and align their interests with the company’s growth objectives.
BeOne Medicines Ltd., a Swiss-incorporated company, announced its unaudited financial results for the third quarter and nine months ending September 30, 2025. The company has provided business updates and revised its financial guidance for the full year. The results, prepared under U.S. GAAP, highlight key business milestones and expectations for continued global expansion and investment. The announcement also includes insights into BeOne’s strategic focus on achieving regulatory milestones and enhancing its market position with its drug candidates.
BeOne Medicines Ltd., a company incorporated in Switzerland, has issued an overseas regulatory announcement regarding its Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarterly period ended September 30, 2025. The announcement highlights the company’s compliance with reporting requirements and provides details on its securities registered on The Nasdaq Global Select Market and The Stock Exchange of Hong Kong Limited. This filing underscores BeOne Medicines’ commitment to transparency and regulatory adherence, potentially reinforcing its credibility and stability in the market.
BeOne Medicines Ltd. has announced a series of waivers and exemptions from compliance with certain Hong Kong Stock Exchange Listing Rules and the Companies Ordinance. These include waivers related to the use of US GAAP, placings to connected persons, and collaboration agreements, among others. The company’s directors have taken responsibility for the accuracy of the information provided and have committed to updating the information sheet if there are material changes. This announcement highlights BeOne Medicines’ strategic moves to navigate regulatory requirements, potentially impacting its operational flexibility and stakeholder relations.
BeOne Medicines Ltd., a Swiss corporation, announced it will release its unaudited financial results for the third quarter of 2025 on November 6, 2025, following the trading hours of the Hong Kong Stock Exchange. The results will be reviewed by the audit committee on the same day, and a conference call with management will be held to discuss the financials, providing stakeholders an opportunity to engage with the company’s leadership.
BeOne Medicines Ltd., formerly known as BeiGene, Ltd., has officially changed its English company name and stock short name as part of its strategic rebranding efforts. The change, effective from May 27, 2025, reflects the company’s new identity and is confirmed by the Registrar of Companies in Hong Kong. The English stock short name for trading on the HKEX will be updated to ‘BEONE MEDICINES’ starting October 22, 2025, while the stock code remains ‘06160’. This rebranding is a significant step in the company’s evolution and may influence its market presence and stakeholder engagement.
BeOne Medicines Ltd., a Swiss corporation, announced the grant of Restricted Share Units (RSUs) and Performance Share Units (PSUs) under its 2016 Share Option and Incentive Plan. On September 30, 2025, the company’s compensation committee granted 36,234 RSUs to 237 grantees and 2,935 PSUs to one grantee, representing approximately 0.03% of the total issued shares. This move is part of the company’s ongoing efforts to incentivize and retain talent, potentially impacting its operational dynamics and stakeholder interests positively.
BeOne Medicines Ltd., a Swiss corporation, announced that Pharmacyclics LLC has decided not to appeal a decision by the U.S. Patent and Trademark Office, which invalidated all claims of a Pharmacyclics patent challenged by BeOne. This resolution, confirmed by a joint stipulation to dismiss related litigation, marks the end of the patent dispute, potentially strengthening BeOne’s position in the market.
BeOne Medicines Ltd., a Swiss corporation, announced the completion of a share purchase under its 2018 Employee Share Purchase Plan (ESPP), allowing eligible employees to buy shares at a 15% discount. A total of 62,962 ADSs, representing 818,506 shares, were purchased by 3,932 participants, equating to approximately 0.05% of the total issued shares. The initiative aims to align employee interests with shareholders and retain talent without performance targets or clawback mechanisms, with 3,179,780 shares still available for future grants.